Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: Results from an open-label 6-year follow-up study

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 122, Issue 1, 2016, Pages 107-118

  Schwarz, T ^a   Spaczynski, M ^b   Kaufmann, A ^c   Wysocki, J ^b   Galaj A ^d   Schulze, K ^e   Suryakiran, P ^f   Thomas, F ^g   Descamps, D ^g  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d VITAMED   (Poland)

^e Vitamed Bydgoszcz ^*  (Germany)

^f GlaxoSmithKline Pharmaceuticals Ltd   (India)

^g GSK   (Belgium)

Author keywords

HPV 16 18 AS04 adjuvanted vaccine; human papillomavirus; persistence

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MIDDLE AGED; PAPILLOMAVIRUS INFECTION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; YOUNG ADULT; AGE; BLOOD; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ADULT; AGE FACTORS; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84920169510     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/1471-0528.13070     Document Type: Article

References (53)

1. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV,. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
2. WHO. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and orevalence in 2012. [ http://globocan.iarc.fr/Pages/fact-sheets-population.aspx ]. Accessed 7 January 2014.
3. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi f, WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005; 6: 204.
4. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
5. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S,. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
7. zur Hausen H,. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92: 690-8.
8. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) 2010. Human Papillomavirus and Related Cancers. Summary Report Update. September 15, 2010.
9. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S,. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010; 202: 1789-99.
10. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453-9.
11. Baseman JG, Koutsky LA,. The epidemiology of human papillomavirus infections. J Clin Virol 2005; 32 (Suppl 1): S16-24.
12. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 (Suppl 10): K1-16.
13. Smith JS, Melendy A, Rana RK, Pimenta JM,. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health 2008; 43 (4 Suppl): S5-25.
14. Woodman CB, Collins SI, Young LS,. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007; 7: 11-22.
15. Bayas JM, Costas L, Munoz A,. Cervical cancer vaccination indications, efficacy, and side effects. Gynecol Oncol 2008; 110 (3 Suppl 2): S11-14.
16. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11: 1048-56.
17. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 518-27.
18. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007; 121: 621-32.
19. Castle PE, Solomon D, Schiffman M, Wheeler CM,. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 1066-71.
20. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 2005; 191: 182-92.
21. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1808-16.
22. Clifford GM, Smith JS, Aguado T, Franceschi S,. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003; 89: 101-5.
23. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006; 119: 2677-84.
24. Lawson MA,. Human papillomavirus infection in adolescent and young women. Mo Med 2008; 105: 42-6.
25. Moscicki AB,. HPV infections in adolescents. Dis Markers 2007; 23: 229-34.
26. Castellsague X, Schneider A, Kaufmann AM, Bosch FX,. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009; 115 (3 Suppl): S15-23.
27. Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009; 5: 332-40.
28. The GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374: 1975-85.
29. Schwarz TF,. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther 2009; 26: 983-98.
30. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, et al. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccin 2011; 7: 958-65.
31. De Carvalho N, Teixeira J, Roteli-Martins CM, Naud P, De Borba P, Zahaf T, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28: 6247-55.
32. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65.
33. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
34. Naud P, Roteli-Martins CM, De Carvalho N, Teixeira J, Borba P, Sanchez N, Zahaf T, et al. HPV-16/18 vaccine: sustained immunogenicity and efficacy up to 9.4 years (Conference abstract). Presented at: International Papillomavirus Conference; September 17-22, 2011; Berlin, Germany.
35. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.
36. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301-14.
37. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012; 8: 390-7.
38. Skinner SR, Szarewski A, Romanowski B, Garland S, Lazcano E, Salmerõn J, et al. Efficacy, safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in women over 25 years: 4-year interim follow-up of the double-blind, randomised VIVIANE study. The Lancet 2014; doi: 10.1016/S0140-6736(14)60920-X [Epub ahead of Print].
39. Verstraeten T, Descamps D, David MP, Zahaf T, Hardt K, Izurieta P, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008; 26: 6630-8.
40. European Medicines Agency. Cervarix human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed). Committee for Medicinal Products for Human Use (CHMP) 2011.
41. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Perona P, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009; 27: 581-7.
42. Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008; 4: 425-34.
43. David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009; 115 (3 Suppl): S1-6.
44. Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, et al. Persistence of immune response 5 years after administration of HPV-16/18 AS04-adjuvanted vaccine to women aged 15-55 years. Asia-Oceania Research Organization in Genital Infection and Neoplasia-2011 Interim Conference (AOGIN). March 17-19 2011, Bali, Indonesia.
45. Petäjä T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011; 129: 2147-57.
46. Ponnappan S, Ponnappan U,. Aging and immune function: molecular mechanisms to interventions. Antioxid Redox Signal 2011; 14: 1551-85.
47. Schwarz TF, Leo O,. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008; 110 (3 Suppl 1): S1-10.
48. Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 324-7.
49. Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010; 8: 260-70.
50. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010; 102: 1653-62.
51. Schwarz TF, Kocken M, Petaja T, Einstein MH, Spaczynski M, Louwers JA, et al. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. Hum Vaccin 2010; 6: 1054-61.
52. Stanley M, Lowy DR, Frazer I,. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006; 24 (Suppl 3) S3: 106-13.
53. Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, et al. A randomized, observer-blinded immunogenicity trial of Cervarix((R)) and Gardasil((R)) Human Papillomavirus vaccines in 12-15 year old girls. PLoS ONE 2013; 8: e61825.